NICE have stated that:
Marstacimab
Tissue factor pathway inhibitor (TFPI) antagonises early coagulation stages by inhibiting tissue factor‐activated FVII (FVIIa) and activated FX (FXa)
The NICE committee noted:
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.